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Cre/LoxP has broad utility for studying the function, development, and oncogenic transformation of pancre-
atic cells in mice. Here we provide an overview of the Cre driver lines that are available for such studies. We
discuss how variegated expression, transgene silencing, and recombination in undesired cell types have
conspired to limit the performance of these lines, sometimes leading to serious experimental concerns.
We also discuss preferred strategies for achieving high-fidelity driver lines and remind investigators of the
continuing need for caution when interpreting results obtained from any Cre/LoxP-based experiment per-
formed in mice.Cre/LoxP and Its Use in Mice
Cre/LoxP is a site-specific recombinase (SSR) system of proven
utility. As for many tissues, Cre/LoxP is frequently used to study
the function, development, and neoplasia of exocrine and endo-
crine cells in the pancreas. The widespread use of Cre/LoxP
arises from its ability to conditionally eliminate or activate
expression of genes in a cell-type- and/or temporal-specific
manner, thereby enabling the cell-, tissue-, and/or develop-
mental-stage-specific functions of genes to be explored within
animal models. While Cre/LoxP is most commonly used in
mice, it and two other SSR systems, Flp/FRT and Dre/Rox,
also have utility in other model organisms (Hoess et al., 1982;
McLeod et al., 1986; Sauer and McDermott, 2004).
Cre, Flp, and Dre, members of the l integrase superfamily of
site-specific recombinases, were cloned from different organ-
isms. Cre is encoded by bacteriophage P1, Flp by the budding
yeast Saccharomyces cerevisiae, and Dre, the most recently
described SSR, by bacteriophage D6. All three recombinases
function as homotetramers and have 34 bp DNA recognition
sequences called LoxP, FRT, and Rox, respectively. The small
size of these recombination recognition sites enables them to
be readily placed within genes where they, in combination with
Cre, Flp, or Dre, enable gene deletions, insertions, inversions,
or translocations.
Over the past two decades, several useful Cre and Flp deriva-
tives have been described. Undoubtedly, the most useful variant
for Cre has been CreER, which prevents Cre from entering the
nucleus in the absence of tamoxifen due to the addition of a
mutated version of the estrogen receptor (ER) hormone-binding
domain (Feil et al., 1996). CreER enables temporal control of
Cre recombination. However, some investigators have found
that efficient tamoxifen-induced recombination is not always
achieved, thereby requiring that multiple doses of tamoxifen be
administered, and that recombination by CreER may occur
weeks after tamoxifen dosing (Reinert et al., 2012). Another use-
ful derivative of Cre is GFPCre, which is a fusion with green fluo-
rescent protein (GFP) that makes it easy to directly identify cells
that express Cre (Gagneten et al., 1997). For Flp, the most useful
derivatives are enhanced Flp (FlpE), which improves thermosta-bilty, and Flpo, a codon-optimized variant that improves expres-
sion (Buchholz et al., 1998; Raymond and Soriano, 2007).
Although both Flp and Dre also have utility in the mouse, partic-
ularly when used in combination with Cre, hereafter we focus our
comments on Cre.
As illustrated in Figure 1, the conditional inactivation of a gene
using Cre/LoxP requires two different genetic components: (1) a
Cre driver line and (2) a target allele in which a gene segment,
usually containing one or more exons, has been flanked with
tandemly oriented LoxP sites (a so-called floxed allele) (Gu
et al., 1994; Orban et al., 1992). Similarly, the required compo-
nents to conditionally activate gene expression are (1) a Cre
driver line and (2) an allele that has been engineered to contain
a lox-stop-lox (LSL) sequence upstream of the coding se-
quences to be expressed. The ubiquitously expressed
ROSA26 gene locus has been used extensively for this purpose
(Soriano, 1999). Indeed, Cre-dependent activation of ROSA26
alleles containing an LSL upstream of b-galactosidase or
different fluorescent proteins (e.g., Gt[ROSA]26Sortm1Sor, Gt
[ROSA]26Sortm1[EYFP]Cos, and Gt[ROSA]26Sortm2Sho; Mao et al.,
2001; Soriano, 1999; Srinivas et al., 2001) has become a stan-
dard tool in the Cre/LoxP tool chest. Not only do these alleles
enable cell lineage tracing, which is fundamentally important in
studies of developmental biology, they can also be used to
readily assess both the sites and efficiency of Cre-mediated
recombination (Sato et al., 2000).
For many years, the development of new floxed alleles was
the limiting factor in using Cre/LoxP to perform a cell- or
tissue-specific gene knockout study. This was due to the need
to perform gene targeting in mouse embryonic stem cells
(mESCs) and then to introduce themutant allele into the germline
of mice. However, as a result of the combined efforts of many
individual laboratories and the large-scale Knockout Mouse
Project (KOMP) (Austin et al., 2004), the number of floxed alleles
available to investigators has skyrocketed. In contrast, there are
fewer truly accurate and reliable Cre driver lines, as we discuss in
detail below.
Optimal use of the Cre/LoxP depends greatly on the functional
precision of the Cre driver line, which is determined in large partCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 9
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Figure 1. Cre-Mediated Recombination in
Mouse Tissues
(A and B) Cre/LoxP can be used to conditionally
eliminate or activate expression of genes. (A)
Conditional gene knockout. A so-called floxed
allele is generated by using gene targeting to flank
a coding exon of a gene of interest with two
tandemly oriented LoxP sites. Ideally, the codon
that is floxed should be of a length that is not
divisible by three since this will cause a frameshift
in the protein being encoded. Intercrossing of a
Cre driver mouse with a floxed-allele mouse will
lead to the excision of the flanked exon and loss of
a functional protein. (B) Conditional gene activa-
tion. A lox-stop-lox (LSL) allele is also generated
by gene targeting. In this case, a gene of interest
(GOI) is engineered to lie downstream of an LSL
cassette containing tandem LoxP sites flanking a
selectable marker, usually neomycin, and multiple
poly(A) signal sequences. Interbreeding of the
LSL-GOI allele to a Cre driver mouse leads to
activation of the GOI in a tissue-specific manner.
This strategy is frequently used to derive reporter
lines whose expression can be activated by Cre.
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of some lines, particularly those made by pronuclear DNAmicro-
injection of short transgenes, can be impaired or destroyed due
to transgene silencing as the lines are passaged. All of these fac-
tors argue for caution when acquiring and using lines, especially
those that do not have a proven history of use. Indeed, when
using any line, investigators need to remain keenly aware of
the limitations of Cre/LoxP itself, in addition to the known defi-
ciencies of a given line, before drawing scientific conclusions
from any experiments that utilize this method.
Pancreas-Specific Cre Driver Lines
An almost certainly incomplete list of Cre driver lines that have
been used in studies of pancreas development and/or function
is shown in Table 1. These 79 driver lines, which were identified
based on either published descriptions or the Beta Cell Biology
Consortium website (www.betacell.org), have been arbitrarily
subdivided into four partially overlapping categories based on
the cell types in which Cre is expressed. Together, these lines
have utilized the promoters of 32 different genes to direct the
expression of Cre.
The first three categories of pancreas-specific Cre driver
genes, endocrine, exocrine, and ductal, reflect the three main
epithelial-derived cell types of the pancreas. These cell types
are easily distinguished by the genes they express. For instance,
peptide hormones have long been used to define individual cells
of the pancreatic islet and digestive enzymes have been used to
mark pancreatic exocrine cells. The fourth category, pancreatic
progenitor cells, is the most diverse since it contains Cre driver
lines that, while they may have been derived for studies of
pancreas development, may also be of utility for studies of
pancreatic function. The utility of this latter group partially stems
from the identification of a series of transcription factors that are
temporally expressed in the pancreatic or prepancreatic endo-
derm during embryogenesis but that later become restricted to
specific adult cell lineages, as illustrated in Figure 2.
Endocrine Cell-Type-Specific Driver Lines
Pancreas-specific endocrine cells have long been defined
by the expression of five different hormones: glucagon, insulin,10 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.somatostatin, ghrelin, and pancreatic polypeptide (PP), which
mark a, b, d, ε, and PP cells, respectively. Thus, genes for
each of these hormones have been used to generate many
different Cre driver lines. Not surprisingly, of the 21 lines that
use endocrine genes to drive Cre expression, 14 utilized an
insulin gene to direct expression to pancreatic b cells. Interest-
ingly, most of the insulin-Cre (Ins-Cre) driver lines have utilized
promoter sequences from species other than mouse. Indeed,
the majority of the reported lines employed the rat Ins2 gene
(often referred to as RIP, rat insulin promoter) (Ahlgren et al.,
1998; Crabtree et al., 2003; Dor et al., 2004; Herrera, 2000; Leiter
et al., 2007; Postic et al., 1999; Ray et al., 1999), but pig (Dahlhoff
et al., 2012) and human (Hamilton-Williams et al., 2003) DNA has
also been used.
The most widely used Ins-Cre driver lines have been
Tg(Ins2-cre)25Mgn, Tg(Ins2-cre)23Herr, and Tg(Ins2-cre/ERT)1Dam.
These lines, all of which are based on the use of short insulin
gene promoter fragments (typically about 0.6 kb), are expressed
in 80% or more of b cells (Dor et al., 2004; Herrera, 2000; Postic
et al., 1999). However, a significant shortcoming of these lines is
that they exhibit leaky expression in the brain and other neuroen-
docrine cell types such as the pituitary gland (Song et al., 2010;
Wicksteed et al., 2010). It is not entirely clear whether the leaky
transgene expression reflects the absence of an essential regu-
latory element or is gene specific, given that Ins2 expression has
been reported in certain types of neurons (Madadi et al., 2008). In
either case, in an effort to increase b cell specificity, several lines
have been derived that utilize longer fragments of DNA contain-
ing the insulin promoter, including Tg(Ins2-cre)1Heed (Ahlgren
et al., 1998) and Tg(Ins2-cre)1Dh(Crabtree et al., 2003). Interest-
ingly, the Tg(Ins2-cre)1Dh line, despite the use of a longer pro-
moter, appears to be expressed in only about 10%–20% of
b cells based on recombination of the Tg(ACTB-Bgeo/ALPP)1Lbe
reporter allele (Crabtree et al., 2003). However, the Tg(Ins1-cre/
ERT)1Lphi line, which utilizes a fragment of the mouse insulin 1
gene, is active in most b cells and does not exhibit expression
in the brain (Wicksteed et al., 2010). Thus, it appears to be the
best cell line available at present for achieving b cell-specific
recombination in a tamoxifen-inducible manner. Because
Table 1. Pancreas-Specific Cre Driver Lines
MGI Name Common Name Type
Driver Gene (Size if Applicable or Known)/
Expression Site(s) in Pancreas Reference
Endocrine Cell Specific
Tg(Ins2-cre)1Heed RIP1-Cre transgene rat Ins2 (0.7 kb)/b cells Ahlgren et al., 1998
Tg(Ins2-cre)6Fcb RIP-Cre transgene rat Ins2 (0.45 kb)/b cells Ray et al., 1999
Tg(Ins2-cre)7Fcb RIP-Cre transgene rat Ins2 (0.45 kb)/b cells Ray et al., 1999
Tg(Ins2-cre)23Herr RIP-Cre transgene rat Ins2 (0.60 kb)/b cells Herrera, 2000
Tg(Ins2-cre)25Mgn RIP-Cre transgene rat Ins2 (0.66 kb)/b cells Postic et al., 1999
Tg(Ins2-cre/ERT)1Dam RIP-CreER transgene rat Ins2 (0.66 kb)/b cells Dor et al., 2004
Tg(Ins2-cre)1Dh RIP7-Cre transgene rat Ins2 (10 kb)/b cells Crabtree et al., 2003
Tg(INS-cre)2Rms HIP-Cre transgene human INS (1.9 kb)/b cells Hamilton-Williams et al., 2003
Tg(Ins2-cre)3Lt RIP-Cre3 transgene rat Ins2 (0.7 kb)/b cells Leiter et al., 2007
Tg(Ins2-cre)5Lt RIP-Cre5 transgene rat Ins2 (0.7 kb)/b cells Leiter et al., 2007
Tg(Ins2-cre)6Lt RIP-Cre6 transgene rat Ins2 (0.7 kb)/b cells Leiter et al., 2007
Tg(INS-icre)18Msdr PIP-iCre transgene porcine INS (1.5 kb)/b cells Dahlhoff et al., 2012
Ins2tm1(cre/ERT2)Kcmm Ins2CreERT2 knock-in mouse Ins2/b cells Nakamura et al., 2011
Tg(Ins1-cre/ERT)1Lphi MIP-CreER transgene mouse Ins1 (8.5 kb)/b cells Wicksteed et al., 2010
Tg(Slc2a2-cre) pGlut2-Cre BAC transgene mouse Slc2a2/b cells Mounien et al., 2010
Tg(Gck-cre)TG7Gsat Gck-Cre BAC transgene mouse Gck/b cells Gong et al., 2003
Tg(Gcg-cre)1Herr GLUC-Cre transgene rat Gcg (1.6 kb)/a cells Herrera, 2000
Tg(Gcg-cre)1Slib Glu-Cre transgene rat Gcg (2.3 kb)/a cells Shen et al., 2009
Tg(Ppy-cre)1Herr PP-Cre transgene rat Ppy (0.6 kb)/PP cells Herrera, 2000
Ssttm1(cre/ERT2)Zjh Sst-CreER knock-in mouse Sst/d cells Taniguchi et al., 2011
Ssttm2.1(cre)Zjh Sst-Cre knock-in mouse Sst/d cells Taniguchi et al., 2011
Ghrltm2.1(cre/EGFP)Suss GhrlCre-GFP knockin/RMCE mouse Ghrl/ε cells Arnes et al., 2012
Acinar Cell Specific
Tg(Amy2-cre)1Herr SV40/Amy-Cre transgene mouse Amy2a (0.9 kb)/acinar cells Kockel et al., 2006
Tg(Cela1-cre/ERT)1Lgdn BAC-Ela-CreErT BAC transgene mouse Cela1/acinar cells Ji et al., 2008
Tg(Ela1-cre/ERT2)1Stof Ela-CreERT transgene rat Cela1 (0.5 kb)/acinar cells Desai et al., 2007
Tg(Ela1-cre/ERT)1Dam Ela-CreERT transgene rat Cela1 enhancer (0.15 kb)-hsp68
promoter/acinar cells
Murtaugh et al., 2005
Tg(Vil-cre)20Syr Vil-Cre transgene mouse Vil1 (9 kb)/acinar cells el Marjou et al., 2004
Tg(Vil-cre/ERT2)23Syr Vil-CreER transgene mouse Vil1 (9 kb)/acinar cells el Marjou et al., 2004
Tg(Vil-cre)1Mka Vil-Cre transgene mouse Vil1 (9 kb)/acinar cells Chen et al., 2003
Tg(Vil-cre)997Gum Vil-Cre transgene mouse Vil1 (12.4 kb)/acinar cells Madison et al., 2002
Cpa1tm1(cre/ERT2)Dam Cpa1CreERT knockin mouse Cpa1/prepancreatic endoderm,
acinar cells
Zhou et al., 2007
Ductal Cell Specific
Krt19tm1(cre/ERT)Ggu CK19CreERT knockin mouse Krt19/ductal cells Means et al., 2008
Tg(CA2-cre)1Subw CAII-Cre transgene human CA2 (1.6 kb)/ductal cells Inada et al., 2008
Tg(CA2-cre/Esr1*)1Subw CAII-CreER transgene human CA2 (1.6 kb)/ductal cells Inada et al., 2008
Muc1tm1.1(cre/ERT2)Lcm Muc1IRES-CreERT2 knockin mouse Muc1/acinar, ductal cells Kopinke and Murtaugh, 2010
Progenitor Cell Specific
Foxa2tm1(cre)Heli Foxa2Cre knockin mouse Foxa2/endoderm Uetzmann et al., 2008
Foxa2tm1.1(icre)Hri Foxa2T2AiCre knockin mouse Foxa2/endoderm Horn et al., 2012
Foxa2tm2.1(cre/Esr1*)Moon Foxa2Cre-ER knockin mouse Foxa2/endoderm Park et al., 2008
Tg(Foxa3-cre)1Khk Foxa3-cre YAC transgene mouse Foxa3/endoderm Lee et al., 2005
Sox17tm1(icre)Heli Sox172A-iCre knockin mouse Sox17/endoderm Engert et al., 2009
Sox17tm2(EGFP/cre)Mgn Sox17GFPCre knockin/RMCE mouse Sox17/endoderm Choi et al., 2012
Cldn6tm1(cre/ERT2)Dam Cldn6CreER knockin mouse Cldn6/endoderm Anderson et al., 2008
(Continued on next page)
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Table 1. Continued
MGI Name Common Name Type
Driver Gene (Size if Applicable or Known)/
Expression Site(s) in Pancreas Reference
Tg(Ipf1-cre)1Tuv Pdx1-Cre transgene mouse Pdx1 (4.5 kb)/prepancreatic
endoderm
Hingorani et al., 2003
Tg(Pdx1-cre)6Cvw Pdx1-Cre transgene mouse Pdx1 (4.5 kb)/prepancreatic
endoderm
Gannon et al., 2000
Tg(Pdx1-cre)1Herr Pdx1-CreLate transgene mouse Pdx1 (4.5 kb)/prepancreatic
endoderm
Herrera, 2000
Tg(Pdx1-cre)1Heed Ipf1-Cre transgene mouse Pdx1 (4.5 kb)/prepancreatic
endoderm
Steneberg et al., 2005
Tg(Pdx1-cre)PBMga Pdx1PB-Cre transgene mouse Pdx1 enhancer (1 kb PstI-BstbII
fragment, areas I and II)-Hsp68 promoter/
embryonic and adult endocrine cells
Wiebe et al., 2007
Tg(Pdx1-cre)XBMga Pdx1XB-Cre transgene mouse Pdx1 enhancer (1.1 kb XhoI-BglII
fragment, area III)-Hsp68 promoter fusion/
prepancreatic endoderm, endocrine cells
Wiebe et al., 2007
Tg(Pdx1-cre/Esr1*)1Mga Pdx1PB-CreERTM transgene mouse Pdx1 enhancer (1 kb PstII-BstEI
fragment, areas I and II)-Hsp68 promoter/
embryonic and adult endocrine cells
Zhang et al., 2005
Tg(Pdx1-cre)89.1Dam Pdx1-CreEarly transgene mouse Pdx1 (5.5 kb)/prepancreatic
endoderm
Gu et al., 2002
Tg(Pdx1-cre/Esr1*)35.6Dam Pdx1-CreER transgene mouse Pdx1 (5.5 kb)/prepancreatic
endoderm
Gu et al., 2002
Tg(Pdx1-cre/Esr1*)35.10Dam Pdx1-CreER transgene mouse Pdx1 (5.5 kb)/prepancreatic
endoderm
Gu et al., 2002
Tg(Pdx1-cre/Esr1*)#Dam Pdx1-CreER transgene mouse Pdx1 (5.5 kb)/prepancreatic
endoderm
Gu et al., 2002
Ptf1atm1(cre)Hnak Ptf1aCre(ex1) knockin mouse Ptf1a/prepancreatic endoderm,
acinar cells
Nakhai et al., 2007
Ptf1atm1.1(cre)Cvw Ptf1aCre knockin/RMCE mouse Ptf1a/prepancreatic endoderm,
acinar cells
Kawaguchi et al., 2002
Ptf1atm2(cre/ESR1)Cvw Ptf1aCre-ERTM knockin/RMCE mouse Ptf1a/prepancreatic endoderm,
acinar cells
Kopinke et al., 2012
Tg(Sox9-cre/ERT2)1Msan Sox9-CreER BAC transgene mouse Sox9/prepancreatic endoderm,
ductal cells
Kopp et al., 2011
Sox9tm1(cre/ERT2)Haak Sox9CreERT2 knockin mouse Sox9/prepancreatic endoderm,
ductal cells
Soeda et al., 2010
Sox9tm3(cre)Crm Sox9-Cre knockin mouse Sox9/prepancreatic endoderm,
ductal cells
Akiyama et al., 2005
Tg(Hnf1b-cre/ERT2)1Jfer Hnf1b-CreER transgene mouse Hnf1b/prepancreatic endoderm,
ductal cells
Solar et al., 2009
Tg(Neurog3-cre)1Dam Ngn3-Cre transgene mouse Neurog3 (6.5 kb)/pre-endocrine
cells
Gu et al., 2002
Tg(NEUROG3-cre)1Herr NGN3-Cre transgene human NEUROG3 (5.7 kb)/pre-endocrine
cells
Desgraz and Herrera, 2009
Tg(Neurog3-cre)24Syos Ngn3-Cre transgene mouse Neurog3 (23 kb)/pre-endocrine cells Yoshida et al., 2004
Tg(Neurog3-cre)C1Able Ngn3-Cre BAC transgene mouse Neurog3/pre-endocrine cells Schonhoff et al., 2004
Tg(Neurog3-cre/Esr1*)1Dam Ngn3-CreER transgene mouse Neurog3 (6.5 kb)/pre-endocrine
cells
Gu et al., 2002
Neurog3tm1.1(cre/ERT)Ggu Neurog3CreERT knockin mouse Neurog3/pre-endocrine cells Wang et al., 2008b
Tg(Nkx2-2*-cre)1Mtse Nkx2.2-Cre transgene mouse Nkx2.2 (1.2 kb)/prepancreatic
endoderm, b cells
Wang et al., 2011
Tg(Nkx2-2-cre/ERT2)1Wdr Nkx2.2-CreER BAC transgene mouse Nkx2.2/prepancreatic endoderm, b
cells
Tsai et al., 2012
(Continued on next page)
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Table 1. Continued
MGI Name Common Name Type
Driver Gene (Size if Applicable or Known)/
Expression Site(s) in Pancreas Reference
Mnx1tm4(cre)Tmj Hb9-Cre knockin mouse Mnx1/prepancreatic endoderm,
endocrine cells
Yang et al., 2001
Myt1tm1(EGFP/icre)Ldh Myt1GFP-Cre knockin mouse Mnx1/prepancreatic endoderm,
endocrine cells
Hudson et al., 2011
Tg(Neurod1-cre)RZ24Gsat Neurod1-Cre BAC transgene mouse Neurod1/endocrine cells Gong et al., 2003
Tg(Pax4-cre)1Dam Pax4-Cre transgene mouse Pax4/endocrine cells Greenwood et al., 2007
Tg(Pax4-cre,GFP)1Pgr Pax4-Cre transgene mouse Pax4 (0.4 kb)/endocrine cells Brink and Gruss, 2003
Pax4tm1(cre/ERT2)Sosa Pax4CreER knockin mouse Pax4/endocrine cells Wang et al., 2008a
Tg(Pax6-cre,GFP)1Pgr Pax6-Cre transgene mouse Pax6 (6.5 kb)/endocrine cells Ashery-Padan et al., 2000
Rfx6tm1.1(EGFP/cre)Mger Rfx6eGFPcre knockin mouse Rfx6/endoderm, endocrine cells Smith et al., 2010
Isl1tm1(cre)Sev Isl1Cre knockin mouse Isl1/endocrine cells Yang et al., 2006
Isl1tm1(cre)Tmj Isl1Cre knockin mouse Isl1/endocrine cells Srinivas et al., 2001
Isl1tm1(cre/Esr1*)Krc Isl1Cre-ERT knockin mouse Isl1/endocrine cells Laugwitz et al., 2005
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expression in neural tissues, some investigators have turned to
the use of Pdx1-Cre, as discussed below, in lieu of an Ins-Cre
driver. However, this can only be done when the gene being
knocked-out exhibits b cell-specific expression since the Pdx1
promoter also drives expression in some regions of the brain,
though to a lesser extent than the insulin promoter.
Fewer lines exist for other islet endocrine cell types. For a cells,
the rat glucagon promoter-driven transgenes have been used to
derive two lines, Tg(Gcg-cre)1Herr and Tg(Gcg-cre)1Slib, both of
which have been reported to efficiently cause recombination in
glucagon-positive cells (Herrera, 2000; Kawamori et al., 2009;
Shen et al., 2009). However, some investigators have noted
lower efficiencies of recombination than reported, perhaps sug-
gesting transgene silencing. For PP cells, a rat PP-driven trans-
gene has been used in Tg(Ppy-cre)1Herr. Lineage tracing with this
PP driver and reporter lines driven by insulin, glucagon, and PP
genes indicate that this driver line causes recombination in
both PP and b cells (Herrera, 2000). Driver lines for d and ε cells
have been generated by knocking Cre into the Sst orGrhl genes,
respectively (Arnes et al., 2012; Taniguchi et al., 2011). Interest-
ingly, GhrlGFPCre marks a large proportion of ε and a cells, and
5% of PP cells, but none of the b or d cells in the adult islet, sug-
gesting that ghrelin-expressing pancreatic progenitor cells
contribute to several cell lineages during development (Arnes
et al., 2012). Also, it should be kept in mind that glucagon,
somatostatin, PP, and ghrelin are all normally expressed in non-
pancreatic enteroendocrine cells, and some of these genes are
also expressed in the brain, so Cre driver lines using these genes
should be expected to exhibit multiple sites of recombination.
Acinar Cell Driver Lines
Cre driver lines for pancreatic acinar cells have generally used
transgenes containing the promoter regions of genes for
digestive enzymes such as elastase and amylase, but the perfor-
mance of these lines has frequently been less than optimal. For
instance, the Tg(Ela1-cre/ERT2)1Stof line made using the rat elas-
tase promoter to express CreER is reported to achieve only about
30%–40% recombination after administration of tamoxifen
(Desai et al., 2007; Means et al., 2005). Use of a transgene con-taining a fusion of elastase 1 enhancer to theHsp68promoter has
yielded the somewhat better-performing Tg(Ela1-cre/ERT)1Dam
line, which results in at least 50%of cells undergoing recombina-
tion after tamoxifen induction (Murtaugh et al., 2005). The highest
performing line in this group appears to be that made using a
bacterial artificial chromosome (BAC)-based Cela1-CreER trans-
gene, since nearly 100% of acini exhibits recombination of a
ROSA26 reporter allele after tamoxifen treatment (Ji et al.,
2008). The Tg(Amy2-cre)1Herr line, which utilized a fragment
from the Amy2a gene, also efficiently marks acinar cells. How-
ever, due to the expression of Amy2a at early developmental
stages, this driver line also results in recombination in many
ductal and islet cells (Kockel et al., 2006).
The Tg(Vil-cre/ERT2)23Syr line, made using the intestinal-
specific villin gene, has also been shown to mark acinar cells.
This appears to be due to recombination in visceral endoderm,
which results in sufficient residual Cre activity to cause scattered
recombination in the intestine, kidney, and pancreas; however,
in pancreatic tissues, recombination is seen only in acinar cells
and not in endocrine or ductal cells (el Marjou et al., 2004; Means
et al., 2005). In addition, both the Ptf1a- and Cpa1-driven CreER
lines can be used to target adult acinar cells. Although both of
these genes are expressed in pancreatic multipotent progenitor
cells (MPCs) during development, they exhibit expression that is
restricted to acinar cells within the pancreas of adult animals
(Kopinke et al., 2012; Zhou et al., 2007).
Ductal Cell Driver Lines
In contrast to pancreatic endocrine and exocrine cells, the iden-
tification of genes that can be used to derive ductal cell-specific
Cre driver lines has been more of a challenge. The Krt19 (CK19),
Muc1, and Car2 (CA2) genes, which have all been used in an
attempt to derive ductal-specific Cre driver lines, exhibit recom-
bination in other pancreatic cell types besides ductal cells.
For instance, Tg(CA2-cre)1Subw causes recombination in adult
ductal, acinar, and a small percentage of endocrine cells (5%)
(Inada et al., 2008). Similarly, a Muc1CreER knockin allele
(Muc1tm1.1(cre/ERT2)Lcm) causes recombination in ductal as well
as acinar cells in adult tissue (Kopinke and Murtaugh, 2010).
The CK19CreERT knockin allele exhibits recombination that isCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 13
Figure 2. Highly Simplified Scheme of
Pancreas Development
The pancreas is an endodermally derived organ
that arises in a stepwise, progressive manner that
involves the specification and differentiation of
definitive endoderm (DE) into specific cell types.
First, DE is specified intoprepancreaticmultipotent
progenitor cells (MPCs). Second, the pancreatic
MPCs are specified into either an acinar, ductal, or
endocrine cell lineage. Third, the endocrine cell
lineage is further specified into five different
endocrine cell types. On account of this progres-
sive cellular differentiation, Cre driver lines that are
expressed early in development will result in
recombination across multiple cell lineages. In
addition, genes that have been used to drive Cre
expression in specific lineages and/or cell types
are indicated in the boxes. For example, the
expression of Ptf1a-Cre, since it is expressed in
pancreaticMPCs during development, will result in
a recombined allele in all threemain pancreatic cell
types in adult animals. Similarly, the expression of
Ngn3-Cre in pre-endocrine progenitor cells will
result in recombined allele being present in all five
endocrine cell types.
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However, this line also marks hepatic ducts, stomach, and intes-
tine when tamoxifen is administered after birth. Nonetheless,
nearly 45% of pancreatic ducts are recombined with the labeling
of only a few (<1%) acinar and endocrine cells. CreER lines driven
by the Sox9 andHnf1b genes can also be used to achieve ductal
cell-specific recombination in adult animals. In both cases, up to
40%–70% of adult ductal cells have been shown to undergo
recombination with only an occasional labeling of acinar and
endocrine cells after activation of CreER by tamoxifen (Kopp
et al., 2011; Solar et al., 2009).
Driver Lines Based on Genes Expressed in Progenitor
Cells
Genes encoding transcription factors that play critical roles in the
development of pancreatic cells, and that are expressed in
specific progenitor cell populations, have been used to derive
44 different Cre driver lines. However, only a few can be put to
practical use in mature animals due to the highly varied nature
of the timing and cell-type specificity of these genes.
Global Endoderm Deleters
During embryogenesis, the pancreas arises from the definitive
endoderm, which is marked by the expression of the Foxa genes
(Foxa1, Foxa2, and Foxa3) and Sox17. Of the three Foxa genes,
Foxa3 is the most endoderm specific and, unlike Foxa1 and
Foxa2, is not expressed in the notochord, floorplate, or ventral
forebrain (Monaghan et al., 1993). For this reason, the
Tg(Foxa3-cre)1Khk line,made using a yeast artificial chromosome
(YAC)-derived transgene, causes recombination throughout the
entire gut endoderm, including in the prepancreatic region (Lee
et al., 2005; Xuan et al., 2012). Foxa2Cre and Foxa2CreER knockin
alleles have also been used to achieve Cre recombination in the
endoderm as well as in other sites of Foxa2 expression such as
the notochord and floorplate (Horn et al., 2012; Park et al., 2008;
Uetzmann et al., 2008). A Sox17GFPCre knockin allele can be used
to achieve recombination throughout the definitive endoderm.
However, Sox17 is also expressed in hemogenic endothelial
cells beginning around embryonic day 9.5 (E9.5), so it too is
not entirely endodermal specific (Choi et al., 2012). A Cldn6CreER14 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.knockin allele is also available for achieving recombination in
definitive endoderm (Anderson et al., 2008).
Pancreas-wide Deleters
The Pdx1 gene is expressed in prepancreatic endoderm starting
at E8.5. As development proceeds, it becomesmore abundant in
b cells, with lower levels in acinar and other endocrine cells
(Jonsson et al., 1994; Offield et al., 1996). Accordingly, Pdx1-
Cre driver lines, such as Tg(Pdx1-cre)89.1Dam, mark all pancreatic
cell types during lineage tracing. However, when the same Pdx1
promoter fragment is used with CreER, such as in Tg(Pdx1-cre/
Esr1*)#Dam in adult animals, recombination is observed only in
the islet and acinar cells (Gu et al., 2002). Most Pdx1-Cre driver
lines, including Tg(Pdx1-cre)6Cvw/Tg(Ipf1-cre)1Tuv, Tg(Pdx1-cre)
1Herr, and Tg(Pdx1-cre)1Heed, have utilized an 4.5 kb Pdx1 pro-
moter fragment and have been found to exhibit mosaic expres-
sion within the Pdx1 expression domain (Gannon et al., 2000;
Herrera, 2000; Steneberg et al., 2005). Interestingly, some of
these Cre drivers exhibit significant differences in terms of their
temporal and spatial activity. Tg(Pdx1-cre)89.1Dam, termed
Pdx-CreEarly, displays early and robust Cre recombinase activity,
while the other Tg(Pdx1-cre)1Herr, termed Pdx-CreLate, has
slightly delayed and more mosaic Cre expression (Heiser et al.,
2006). It is worth noting that besides marking pancreas, Pdx1
driver alleles also cause recombination in the duodenum, antral
stomach, bile duct, and, as recently shown, hypothalamus and
inner ear (Honig et al., 2010; Schonhoff et al., 2004; Song
et al., 2010; Wicksteed et al., 2010; Yoshida et al., 2004).
By utilizing different enhancer fragments derived from regula-
tory regions located upstream of the Pdx1 promoter, additional
lines have been derived that express Cre in a more restricted,
but still pancreas-specific, manner. The Tg(Pdx1-cre)PBMga
line, which fuses a 1 kb DNA fragment (Pdx1PB) containing regu-
latory areas I and II to the Hsp68 promoter, causes Cre expres-
sion not only in b cells, but also to some extent in all endocrine
cells (Wiebe et al., 2007). Conversely, Tg(Pdx1-cre)XBMga, a Cre
driver transgene containing regulatory area III (Pdx1XB)
mediates recombination throughout the developing pancreas
similar to the 4.5 kb Pdx1 promoter (Wiebe et al., 2007). The
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Pdx1PB-CreER) allows spatial and temporal control of gene
manipulation specifically in pancreatic islets (Zhang et al., 2005).
Ptf1a is another gene that is crucial for pancreatic organogen-
esis. Unlike Pdx1, the expression of Ptf1a within the developing
gut is restricted to cells that only give rise to the pancreas, so it
does not cause recombination in the distal stomach or proximal
gut. Lineage tracing experiments using a Ptf1aCre knockin allele
have demonstrated recombination in all three main pancreatic
cell types (Kawaguchi et al., 2002), consistent with the expres-
sion of Ptf1a in pancreatic MPCs. In addition to being
expressed in the pancreas, Ptf1a is also expressed in the devel-
oping cerebellum and retina (Nakhai et al., 2007).
Highly specific, pancreas-wide gene knockouts have been
achieved using driver mice derived using the Cpa1, Sox9,
and Hnf1b genes. For instance, the Cpa1-CreER allele
(Cpa1tm1[cre/ERT2]Dam), due to the expression of Cpa1 in pancre-
atic MPCs early during pancreas development, results in recom-
bination in all three pancreatic lineages. However, tamoxifen
must be administered before E14.5 for this outcome to be
achieved (Zhou et al., 2007). Similarly, Sox9 and Hnf1b, which
are expressed in the pancreatic epithelium beginning at E10.5,
cause recombination in endocrine, acinar, and duct cells (Kopp
et al., 2011; Solar et al., 2009). Thus, provided that tamoxifen
is administered after E13.5, theHnf1b-CreER driver linewill cause
recombination only in ductal and endocrine cells, not in acinar
cells (Solar et al., 2009).
Endocrine Lineage-Specific Deleters
The emergence of pancreatic endocrine cells from pancreatic
endoderm is triggered by the expression of Neurog3 (Ngn3)
beginning around E13.5 (Gradwohl et al., 2000). Several Ngn3-
Cre driver lines have been described, some of which utilize
CreER. Lineage tracing studies using Tg(Neurog3-cre)1Dam and
Tg(Neurog3-cre/Esr1*)1Dam have shown high-efficiency recom-
bination in all endocrine cell types in the islet (Gu et al., 2002).
In addition, several other Ngn3-Cre driver lines have also been
used to mark endocrine cells in the pancreas. These include
Tg(NEUROG3-cre)1Herr, which utilizes a 5.7 kb fragment of the
human NEUROG3 gene (Desgraz and Herrera, 2009),
Tg(Neurog3-cre)24Syos, which is driven by a 23 kb fragment of
the Ngn3 gene (Yoshida et al., 2004), the BAC transgenic line
Tg(Neurog3-cre)C1Able (Schonhoff et al., 2004), and a Ngn3CreER
knockin allele (Neurog3tm1.1(cre/ERT)Ggu; Wang et al., 2008b).
Since expression of Neurog3 is not restricted to pancreatic
endocrine cells, these driver lines also cause recombination in
gastrointestinal cells, the neural system, and testis (Schonhoff
et al., 2004; Song et al., 2010; Yoshida et al., 2004). Prudent
use of Neurog3-Cre driver lines requires consideration of the
fact that Neurog3 is expressed in a narrow developmental time
window, and recombination may occur in cells that no longer
express Neurog3 due to the perdurance of Cre. Indeed, this
consideration should be applied to all Cre lines driven by tran-
siently expressed genes.
Other proendocrine transcription factor genes that have been
used to drive Cre expression includeNeurod1, Pax4,Myt1, Rfx6,
Isl1, Nkx2.2, Pax6, and Mnx1. All are characterized by recombi-
nation in other sites besides the pancreatic endocrine cells as
well as major differences in their timing of expression. For
instance, Pax4-Cre efficiently labels all four pancreatic endo-crine cell lineages, whereas Rfx6-Cre causes recombination in
all tissues derived from endoderm, presumably due to expres-
sion at an earlier time during development (Smith et al., 2010).
Moreover, many proendocrine factors are also expressed in neu-
ral and other organ systems, making it necessary to consider
whether nonpancreatic sites of expression will impact experi-
mental design and interpretation. Pax6, for instance, is ex-
pressed in the eye lens, and Isl1 is expressed in the mesoderm
and plays an important role in heart development (Ashery-Padan
et al., 2000; Gong et al., 2003; Hudson et al., 2011; Wang et al.,
2011; Yang et al., 2001, 2006). Because of their more complex
expression patterns, these lines are not widely used in meta-
bolism-oriented studies in adult animals.
Limitations of Short Promoter Fragment Transgenes
Of the driver genes listed in Table 1, 45 (well over half) weremade
using relatively short driver gene (promoter) fragments, and the
other 34 drivers were made by BAC transgenesis (8) or gene
targeting (26). This is a vitally important consideration since the
pronuclear microinjection of DNA results in both randomly inte-
grated DNA fragments and variable transgene copy numbers,
both of which can negatively impact the accuracy and duration
of Cre expression. Moreover, short driver DNA fragments may
lack key cis-regulatory elements important to obtain precise
cell- or tissue-specific gene expression.
Randomly inserted transgenes are characterized not only by
inexact expression patterns, but sometimes also by the silencing
of gene transcription. These expression artifacts are due either to
position effect variegation (PEV) or position effect silencing, a
phenomenon that was first described in studies using
Drosophila. PEV was first described as variable gene silencing
of the white gene (which is responsible for red eye color) when
it was translocated into a heterochromatic region of DNA.
Silencing of the white gene resulted in easily discernible red
and white patches in the mature Drosophila eye due to subpop-
ulations of cells that exhibited a mosaic pattern of gene expres-
sion (Henikoff, 1992). Studies of this phenomenon led to the
conclusion that alterations in chromatin-associated proteins
can have a dramatic effect on the expression of genes, both
positively and negatively, whether they are endogenous or a
randomly inserted transgene (Ebert et al., 2006; Karpen, 1994;
Reuter and Spierer, 1992).
Gene silencing, which is analogous to PEV, has since been
observed in yeast, plants, and mammals (Fischer et al., 2006;
Tham and Zakian, 2002). Factors governing the silencing
of transgenes include the integration site, the number of copies
of transgene in an integrated array, and the components of a
transgene (Martin and Whitelaw, 1996). Furthermore, both DNA
methylation and epigenetic modifications are known to silence
gene expression, with the expression of transgenes integrated
near heterochromatic regions being inhibited (Law and
Jacobsen, 2010; Meyer, 2000). Similarly, the integration of trans-
genes near telomeres may also affect the extent of variegation.
Tissues with more heterochromatin also exhibit a higher degree
of transgene silencing.
Transgene copy number is well known to contribute to trans-
gene silencing, with an inverse relationship between copy num-
ber and expression level often observed. The fact that high-copy
number lines are often transcriptionally inactive is thought to beCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 15
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However, the existence of some transgenes with copy-number-
dependent expression argue for the existence of regulatory ele-
ments, e.g., locus control regions (LCRs), that may prevent this
repeat-induced silencing. Other components of transgenes,
such as enhancers and matrix attachment regions (MARs), can
positively influence expression (Harraghy et al., 2008; Kioussis
and Festenstein, 1997). Conversely, the presence of plasmid
sequences, as well as bacterial genes such as LacZ (which are
CpG-rich and prone to methylation), have long been known to
impair transgene expression, as have viral DNA sequences
such as long terminal repeats (LTRs). In addition, patterns of
transgene expression are sometimes affected by age and
genetic background of the mice. Silencing of transgene ex-
pression can occur within a single generation or more gradually
over several generations. Finally, the genetic background may
also influence the extent of variegation, perhaps due to chromo-
somal differences between inbred strains of mice (Allen et al.,
1990).
Approaches for Obtaining High-Fidelity Cre Driver Line
Expression
Due to the deficiencies of transgenes containing short driver
DNA fragments, two other strategies have gained favor for
deriving Cre driver lines that exhibit expression patterns that
closely match that of the driver gene. The first strategy involves
the use of BACs (Wang et al., 2009). The advantage of using
BAC-derived transgenes to make tissue- or cell-type-specific
Cre driver lines lies in the large size of DNA fragments that
BAC clones contain: typically over 100 kb and sometimes even
more than 200 kb. As the amount of flanking DNA increases so
does the prospect for faithful reproduction of endogenous
expression patterns (Giraldo and Montoliu, 2001). Even so,
some BAC-derived Cre transgenes may lack key regulatory
elements and may fail to fully mimic expression of the endoge-
nous gene. Methods for manipulating BAC DNA, referred to
as BAC recombineering, have been described that are simple
and reliable to perform. In addition, indexed BAC libraries
from the genomic DNA of several commonly used strains of
mice have been available for years (Osoegawa et al., 2000;
Sharan et al., 2009). While BAC-derived transgenes may be
less susceptible to position effects than more conventional
transgenes, variegated expression and silencing of BAC-derived
transgenes has nonetheless been reported (Alami et al., 2000).
This suggests that some BAC transgenes, despite their long
length, may still fall under the influence of the surrounding
chromatin environment.
The second method for deriving new Cre driver lines, and the
one which we generally prefer, is to perform gene targeting in
mouse ESCs to place Cre in a fully native genetic context (e.g.,
a gene knockin). This strategy results in Cre being expressed
in a manner that reflects all endogenous regulatory elements,
even those that are located a long distance from the transcrip-
tional start site. However, while this method is almost certain
to result in a high-fidelity expression pattern, it has three draw-
backs. First, it is time consuming to perform gene targeting in
mESCs. Second, unless the gene is engineered to maintain
expression of the gene that is targeted, haploinsufficiency will
occur. Third, breeding a Cre driver allele to homozygosity causes16 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.the knockout of genes that are often essential for the develop-
ment or life of the animal. While these issues can be overcome
by the careful engineering of a Cre-expressing allele to retain
expression of the endogenous gene, it adds additional technical
complexity when designing a targeting vector. Nonetheless, we
believe that the high-fidelity expression of Cre that is nearly
always achieved outweighs these limitations.
The derivation of new Cre knockin mouse lines can be
facilitated by two other technologies. The first is recombinase-
mediated cassette exchange (RMCE), which allows Cre-medi-
ated insertion of a target cassette into a predefined genomic
locus, or a loxed cassette acceptor (LCA) allele, that contains in-
verted (Feng et al., 1999) or heterotypic LoxP sites (Araki et al.,
2002). The principal advantage of this method is that it allows
multiple allelic variants to be made at a defined genetic location
with greater ease than can be achieved by repetitive gene target-
ing. Thus, once a genomic locus has been converted into a LCA
allele, it becomes possible to readily generate lines of mice that
express, for instance, Cre, CreER, or GFPCre. As an effort within
the Beta Cell Biology Consortium, we (and others) have gener-
ated mESCs containing LCAs for over a dozen genes, many of
which are useful for deriving driver alleles for expressing SSRs,
the reverse tetracycline transactivator (rtTA), or various fluores-
cent protein (FP) reporters. The genes for which LCA alleles
have been derived include Pdx1 (Potter et al., 2012), Ptf1a (Bur-
lison et al., 2008), Nkx2.2 (Papizan et al., 2011), Sox17 (Choi
et al., 2012), Neurog3, Insm1, Ghrl (Arnes et al., 2012), Sst, and
Ins2, and several of these LCA alleles have already been used
to derive new Cre or CreER drivers (Arnes et al., 2012; Choi
et al., 2012; Kopinke et al., 2012).
While RMCE can facilitate the generation of new Cre driver
alleles, this technology may soon be superseded by the use
of zinc finger nucleases (Urnov et al., 2010), transcription
activator-like effector nucleases (TALENs) (Joung and Sander,
2013), and the clustered regularly interspaced short palindromic
repeats/CRISPR-associated (CRISPR/Cas) system (Cong et al.,
2013). These emerging technologies greatly improve the effi-
ciency of gene targeting, thereby making it possible to more
readily engineer loci to express any of the SSRs or their deriva-
tives (Cui et al., 2011).
Despite the existence of a seemingly large number of Cre
driver lines, there remains a need for more high-fidelity driver
lines, not only for Cre, but also for other SSRs. Indeed, given
that some mouse models require the simultaneous activation
and/or knockout of two different genes, reliable Flpo and Dre
drivers will likely also be of value. Thus, we encourage efforts
directed at deriving new SSR driver lines whose expression
patterns are accurately defined.
A Continuing Need for Caution
While Cre/LoxP has become an indispensible tool for performing
genetic manipulations in the mouse, the experience of many in-
vestigators has also taught us about some of the limitations of
the system. For instance, it is important to not extrapolate from
one recombination event to another since recombination at
one floxed allele in a cell does not always mean that a second
floxed allele in the same cell will have also recombined
(Liu et al., 2013). This is due to apparent differences in the sus-
ceptibility of alleles to Cre-mediated recombination (Vooijs
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given cell type may differ from that in a second cell type, even
when the amount of Cre in the cell is the same (Long and Rossi,
2009). Also, even when a driver line is of high efficiency and
specificity, recombination at a given floxed allele may vary due
to differences in the background strains used.
Both the timing and efficiency of Cre recombination can also
greatly influence an experimental outcome. For example, the
use of different Pdx1-Cre deleter mice in studies ofWnt signaling
during early pancreas development led to markedly different
experimental conclusions (Dessimoz et al., 2005; Heiser et al.,
2006; Murtaugh et al., 2005), an outcome that emphasizes the
continuing need for caution, particularly with respect to data
interpretation. Indeed, we believe it is prudent to maintain
some skepticism about all published descriptions of Cre reporter
lines and to occasionally reassess both the efficiency and spec-
ificity of Cre recombination. Finally, it may be vital to use a Cre-
only control to exclude any unexpected phenotypes caused by
Cre itself, as described in the accompanying perspective by
Harno et al. (2013).ACKNOWLEDGMENTS
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